metformin has been researched along with Sensitivity and Specificity in 80 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine if the use of metformin in people with prediabetes (impaired glucose tolerance or impaired fasting glucose) would prevent or delay the onset of frank type 2 diabetes mellitus." | 8.85 | Treating prediabetes with metformin: systematic review and meta-analysis. ( Godwin, M; Lilly, M; Lily, M, 2009) |
| "In this study, we aim to determine the effect of metformin on osteoarthritis (OA) development and progression." | 7.96 | Metformin limits osteoarthritis development and progression through activation of AMPK signalling. ( Chen, D; Feng, S; Huang, J; Li, J; Liu, WX; Liu-Bryan, R; Lu, K; Ning, G; Oh, CD; Pan, H; Wang, T; Xiao, G; Xing, C; Yi, D; Zhang, B; Zhao, L, 2020) |
| "Background Metformin associated lactic acidosis (MALA) is a serious adverse event with a high mortality rate of 30-50%." | 7.96 | Identifying patients with metformin associated lactic acidosis in the emergency department. ( de Meijer, A; Gedik, A; Jansman, FGA; Taxis, K; van 't Riet, E; van Berlo-van de Laar, IRF, 2020) |
| "To evaluate serum visfatin levels and to determine the effects of metformin treatment on visfatin levels in patients with polycystic ovary syndrome (PCOS)." | 7.76 | Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. ( Cakal, E; Engin-Ustun, Y; Ozkaya, M; Ustun, Y, 2010) |
| "The anti-hyperglycemic medication metformin has potential to be the first drug tested to slow aging in humans." | 5.01 | Taming expectations of metformin as a treatment to extend healthspan. ( Konopka, AR; Miller, BF, 2019) |
| "To determine if the use of metformin in people with prediabetes (impaired glucose tolerance or impaired fasting glucose) would prevent or delay the onset of frank type 2 diabetes mellitus." | 4.85 | Treating prediabetes with metformin: systematic review and meta-analysis. ( Godwin, M; Lilly, M; Lily, M, 2009) |
| "In this study, we aim to determine the effect of metformin on osteoarthritis (OA) development and progression." | 3.96 | Metformin limits osteoarthritis development and progression through activation of AMPK signalling. ( Chen, D; Feng, S; Huang, J; Li, J; Liu, WX; Liu-Bryan, R; Lu, K; Ning, G; Oh, CD; Pan, H; Wang, T; Xiao, G; Xing, C; Yi, D; Zhang, B; Zhao, L, 2020) |
| "Background Metformin associated lactic acidosis (MALA) is a serious adverse event with a high mortality rate of 30-50%." | 3.96 | Identifying patients with metformin associated lactic acidosis in the emergency department. ( de Meijer, A; Gedik, A; Jansman, FGA; Taxis, K; van 't Riet, E; van Berlo-van de Laar, IRF, 2020) |
| "To compare the effects of sulfonylureas and metformin on CVD outcomes (acute myocardial infarction and stroke) or death." | 3.78 | Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. ( Elasy, TA; Greevy, RA; Griffin, MR; Grijalva, CG; Hung, AM; Liu, X; Murff, HJ; Roumie, CL, 2012) |
| "To evaluate serum visfatin levels and to determine the effects of metformin treatment on visfatin levels in patients with polycystic ovary syndrome (PCOS)." | 3.76 | Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. ( Cakal, E; Engin-Ustun, Y; Ozkaya, M; Ustun, Y, 2010) |
| " Average increases in insulin dosage with exenatide and placebo were 13 U/d and 20 U/d." | 2.76 | Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. ( Bergenstal, RM; Buse, JB; Glass, LC; Heilmann, CR; Hoogwerf, BJ; Kwan, AY; Lewis, MS; Rosenstock, J, 2011) |
| "Metformin is an oral antihyperglycemic agent used in the therapy of noninsulin-dependent diabetic patients." | 2.69 | Determination of plasma metformin by a new cation-exchange HPLC technique. ( Bonfigli, AR; Coppa, G; De Sio, G; Gregorio, F; Manfrini, S; Testa, I; Testa, R, 1999) |
| "They improve metabolic control in type 2 diabetes in monotherapy and also in combination with metformin, sulphonylurea and thiazolidinediones." | 2.45 | Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. ( Ahrén, B, 2009) |
| "The risk of malignant brain tumors associated with metformin use has rarely been investigated in humans." | 1.62 | Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus. ( Tseng, CH, 2021) |
| "A novel, selective and sensitive method is developed for simultaneous estimation of canagliflozin and metformin and successfully applied to fast and fed pharmacokinetic studies in healthy Indian volunteers." | 1.56 | Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ( Gujar, S; Mungantiwar, A; Pandita, N; Wattamwar, T, 2020) |
| "A total of 52,544 individuals with type 2 diabetes were eligible." | 1.46 | Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications. ( Armstrong, J; Fox, KP; Mandl, KD; Steinberg, G; Tseng, YJ, 2017) |
| "A simple, precise and stability-indicating HPLC method was developed and validated for the simultaneous determination of metformin hydrochloride (MET) and vildagliptin (VLG) in pharmaceutical dosage forms." | 1.40 | Development of validated stability indicating assay method for simultaneous estimation of metformin hydrochloride and vildagliptin by RP-HPLC. ( Pradeepkumar, M; Rao, VJ; Satheeshkumar, N; Shanthikumar, S, 2014) |
| " The applicability of the method for human pharmacokinetic studies was demonstrated by dosing a healthy male volunteer with 500-mg metformin hydrochloride as a single oral dose; plasma and urine concentrations were measured for 24 hours." | 1.40 | Quantitation of metformin in human plasma and urine by hydrophilic interaction liquid chromatography and application to a pharmacokinetic study. ( Brøsen, K; Christensen, MM; Nielsen, F, 2014) |
| " The method is simple, selective, robust economic and has been applied successfully to more than 2000 plasma samples as part of pharmacokinetic study in humans." | 1.39 | Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ( Bharathi, DV; Jagadeesh, B; Narayana, VS; Pankaj, C; Venkateswarulu, V, 2013) |
| " The presented HPLC-MS/MS method was proved to be suitable for the pharmacokinetic study of metformin hydrochloride and glipizide tablets in healthy volunteers after oral administration." | 1.39 | Simultaneous quantification of metformin and glipizide in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ( Deng, Y; Li, F; Li, N; Qin, F; Yu, J, 2013) |
| " The developed assay was applied to a pharmacokinetic study in rats." | 1.39 | LC-MS/MS-ESI method for simultaneous quantitation of metformin and repaglinidie in rat plasma and its application to pharmacokinetic study in rats. ( Giri, S; Mullangi, R; Pawar, G; Rajagopal, S; Sharma, K; Yadam, S, 2013) |
| "Metformin is a well-known oral antihyperglycemic drug used in treatment of type II diabetes." | 1.38 | Determination of metformin in rat plasma by HILIC-MS/MS combined with Tecan automation and direct injection. ( Han, F; Huang, QM; Lin, ZJ; Weng, N; Zhang, W; Zhao, H, 2012) |
| "Metformin was the antidiabetic drug at the highest concentration in wastewater and surface water (up to 253 ng L(-1) and 104 ng L(-1), respectively)." | 1.38 | High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples. ( Alonso, E; Aparicio, I; Buchberger, W; Martín, J; Santos, JL, 2012) |
| "Cases of prostate cancer were matched up to ten controls on year of birth, date of cohort entry, and duration of follow-up." | 1.37 | Metformin and the incidence of prostate cancer in patients with type 2 diabetes. ( Azoulay, L; Dell'Aniello, S; Gagnon, B; Pollak, M; Suissa, S, 2011) |
| " The method was applicable to clinical pharmacokinetic study of metformin and rosiglitazone in healthy volunteers following oral administration." | 1.37 | Simultaneous determination and pharmacokinetic study of metformin and rosiglitazone in human plasma by HPLC-ESI-MS. ( Chen, L; Ma, A; Shen, M; Zhou, Z, 2011) |
| " The method was subsequently used to determine the oral pharmacokinetics of metformin and sitagliptin after dosing to male mice." | 1.37 | Simultaneous quantitation of metformin and sitagliptin from mouse and human dried blood spots using laser diode thermal desorption tandem mass spectrometry. ( Denn, M; Gallagher, RT; Peter, RM; Swales, JG, 2011) |
| "A simple, precise, rapid, and reproducible reversed-phase high-performance liquid chromatography method is developed for the simultaneous estimation of metformin hydrochloride (MET), pioglitazone hydrochloride (PIO), and glimepiride (GLP) present in multicomponent dosage forms." | 1.35 | Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and glimepiride by RP-HPLC in tablet formulation. ( Amin, M; Jain, D; Jain, S, 2008) |
| " The method was applied to determine the pharmacokinetic parameters: C(max) (1667." | 1.34 | Simple and rapid method determination for metformin in human plasma using high performance liquid chromatography tandem mass spectrometry: application to pharmacokinetic studies. ( Barroso, PT; Ferreira-Filho, M; Marques, MA; Pinto, DP; Pinto, OW; Soares, Ade S; Werneck-Barroso, E, 2007) |
| " The simultaneous determination of these analytes is important for the routine monitoring of diabetic patients who take combination medications and for studying the pharmacokinetics of the combined dosage forms." | 1.33 | The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma. ( Aburuz, S; McElnay, J; Millership, J, 2005) |
| "Metformin treatment significantly blunted the ethanol effect by >60%." | 1.33 | Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. ( Arteel, GE; Beier, JI; Bergheim, I; Davis, MA; Duveau, I; Guo, L; Lambert, JC; Luyendyk, JP; Roth, RA, 2006) |
| "A simple, rapid, and precise reversed-phase liquid chromatographic method is developed for the simultaneous determination of metformin in combination with rosiglitazone." | 1.32 | Simultaneous determination of metformin in combination with rosiglitazone by reversed-phase liquid chromatography. ( Bagool, MA; Deo, AA; Kolte, BL; Raut, BB; Shinde, DB, 2004) |
| "Buformin and metformin were detected at 236 nm, and eluted 9." | 1.32 | A validated HPLC method with ultraviolet detection for the determination of buformin in plasma. ( Cheng, CL; Chou, CH; Huang, CC, 2004) |
| "Metformin was well resolved at a retention time of about 5 min." | 1.30 | Determination of metformin in plasma by high-performance liquid chromatography after ultrafiltration. ( Nabbie, F; Swanson, B; Vesterqvist, O, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (5.00) | 18.2507 |
| 2000's | 33 (41.25) | 29.6817 |
| 2010's | 37 (46.25) | 24.3611 |
| 2020's | 6 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Scott, NP | 1 |
| Teoh, EJ | 1 |
| Flight, H | 1 |
| Jones, BE | 1 |
| Niederer, J | 1 |
| Mustata, L | 1 |
| MacLean, GM | 1 |
| Roy, PG | 1 |
| Remoundos, DD | 1 |
| Snell, C | 1 |
| Liu, C | 1 |
| Gleeson, FV | 1 |
| Harris, AL | 1 |
| Lord, SR | 1 |
| McGowan, DR | 1 |
| Chen, H | 1 |
| Lin, C | 1 |
| Lu, C | 1 |
| Wang, Y | 2 |
| Han, R | 1 |
| Li, L | 1 |
| Hao, S | 1 |
| He, Y | 1 |
| Li, J | 1 |
| Zhang, B | 1 |
| Liu, WX | 1 |
| Lu, K | 1 |
| Pan, H | 1 |
| Wang, T | 1 |
| Oh, CD | 1 |
| Yi, D | 1 |
| Huang, J | 1 |
| Zhao, L | 1 |
| Ning, G | 1 |
| Xing, C | 1 |
| Xiao, G | 1 |
| Liu-Bryan, R | 1 |
| Feng, S | 1 |
| Chen, D | 1 |
| Wattamwar, T | 1 |
| Mungantiwar, A | 1 |
| Gujar, S | 1 |
| Pandita, N | 1 |
| van Berlo-van de Laar, IRF | 1 |
| Gedik, A | 1 |
| van 't Riet, E | 1 |
| de Meijer, A | 1 |
| Taxis, K | 1 |
| Jansman, FGA | 1 |
| de Carvalho Matos, L | 1 |
| Calixto, LA | 1 |
| Junqueira Garcia, MT | 1 |
| Tseng, CH | 1 |
| Tseng, YJ | 1 |
| Steinberg, G | 1 |
| Fox, KP | 1 |
| Armstrong, J | 1 |
| Mandl, KD | 1 |
| Mowaka, S | 1 |
| Ayoub, BM | 1 |
| Peng, Y | 1 |
| Chang, Q | 1 |
| Yang, N | 1 |
| Gu, S | 1 |
| Zhou, Y | 1 |
| Yin, L | 1 |
| Aa, J | 1 |
| Wang, G | 1 |
| Sun, J | 1 |
| Brito Santos, R | 1 |
| Pereira da Silva, R | 1 |
| Akihiro Melo Otsuka, F | 1 |
| de Jesus Trindade, D | 1 |
| Costa Santos, A | 1 |
| Reis Matos, H | 1 |
| Gedawy, A | 1 |
| Al-Salami, H | 1 |
| Dass, CR | 1 |
| Konopka, AR | 1 |
| Miller, BF | 1 |
| Opdebeeck, B | 1 |
| Maudsley, S | 1 |
| Azmi, A | 1 |
| De Maré, A | 1 |
| De Leger, W | 1 |
| Meijers, B | 1 |
| Verhulst, A | 1 |
| Evenepoel, P | 1 |
| D'Haese, PC | 1 |
| Neven, E | 1 |
| Hendriks, T | 1 |
| Al Ali, L | 1 |
| Maagdenberg, CG | 1 |
| van Melle, JP | 1 |
| Hummel, YM | 1 |
| Oudkerk, M | 1 |
| van Veldhuisen, DJ | 1 |
| Nijveldt, R | 1 |
| van der Horst, ICC | 1 |
| Lipsic, E | 1 |
| van der Harst, P | 1 |
| Dias, BCL | 1 |
| Fachi, MM | 1 |
| de Campos, ML | 1 |
| Degaut, FLD | 1 |
| Peccinini, RG | 1 |
| Pontarolo, R | 1 |
| Jagadeesh, B | 1 |
| Bharathi, DV | 1 |
| Pankaj, C | 1 |
| Narayana, VS | 1 |
| Venkateswarulu, V | 1 |
| Satheeshkumar, N | 1 |
| Pradeepkumar, M | 1 |
| Shanthikumar, S | 1 |
| Rao, VJ | 1 |
| Nielsen, F | 1 |
| Christensen, MM | 1 |
| Brøsen, K | 1 |
| Zhang, X | 1 |
| Wang, X | 1 |
| Vernikovskaya, DI | 1 |
| Fokina, VM | 1 |
| Nanovskaya, TN | 1 |
| Hankins, GD | 1 |
| Ahmed, MS | 1 |
| Shi, L | 1 |
| Tan, GS | 1 |
| Zhang, K | 1 |
| Michel, D | 1 |
| Gaunt, MC | 1 |
| Arnason, T | 1 |
| El-Aneed, A | 1 |
| Truong, V | 1 |
| Helmy, R | 1 |
| Ren, S | 1 |
| Schenk, D | 1 |
| Waterhouse, D | 1 |
| Reddy, S | 1 |
| Ahmed, I | 1 |
| Ahmad, I | 1 |
| Mukhopadhyay, A | 1 |
| Thangam, S | 1 |
| Scherf-Clavel, M | 1 |
| Högger, P | 1 |
| Katz, LL | 1 |
| Anderson, BJ | 1 |
| McKay, SV | 1 |
| Izquierdo, R | 1 |
| Casey, TL | 1 |
| Higgins, LA | 1 |
| Wauters, A | 1 |
| Hirst, K | 1 |
| Nadeau, KJ | 1 |
| Bertsimas, D | 1 |
| Kallus, N | 1 |
| Weinstein, AM | 1 |
| Zhuo, YD | 1 |
| Barry, E | 1 |
| Roberts, S | 1 |
| Oke, J | 1 |
| Vijayaraghavan, S | 1 |
| Normansell, R | 1 |
| Greenhalgh, T | 1 |
| Ma, F | 1 |
| Qiao, L | 1 |
| Yue, H | 1 |
| Xie, S | 1 |
| Zhou, X | 1 |
| Jiang, M | 1 |
| Zhang, W | 2 |
| Qi, J | 1 |
| Wang, L | 1 |
| Xu, K | 1 |
| Jain, D | 2 |
| Jain, S | 1 |
| Amin, M | 1 |
| Ozkaya, M | 1 |
| Cakal, E | 1 |
| Ustun, Y | 1 |
| Engin-Ustun, Y | 1 |
| Lily, M | 1 |
| Lilly, M | 1 |
| Godwin, M | 1 |
| Ahrén, B | 1 |
| Vazquez-Martin, A | 1 |
| Oliveras-Ferraros, C | 1 |
| Del Barco, S | 1 |
| Martin-Castillo, B | 1 |
| Menendez, JA | 1 |
| Giamouzis, G | 1 |
| Triposkiadis, F | 1 |
| Butler, J | 1 |
| Discenza, L | 1 |
| D'Arienzo, C | 1 |
| Olah, T | 1 |
| Jemal, M | 1 |
| Arayne, MS | 1 |
| Sultana, N | 1 |
| Zuberi, MH | 1 |
| Siddiqui, FA | 1 |
| Hsieh, Y | 1 |
| Galviz, G | 1 |
| Hwa, JJ | 1 |
| Buse, JB | 1 |
| Bergenstal, RM | 1 |
| Glass, LC | 1 |
| Heilmann, CR | 1 |
| Lewis, MS | 1 |
| Kwan, AY | 1 |
| Hoogwerf, BJ | 1 |
| Rosenstock, J | 1 |
| Azoulay, L | 1 |
| Dell'Aniello, S | 1 |
| Gagnon, B | 1 |
| Pollak, M | 1 |
| Suissa, S | 1 |
| Chen, L | 1 |
| Zhou, Z | 2 |
| Shen, M | 1 |
| Ma, A | 1 |
| Swales, JG | 1 |
| Gallagher, RT | 1 |
| Denn, M | 1 |
| Peter, RM | 1 |
| Georgiţă, C | 2 |
| Albu, F | 2 |
| David, V | 2 |
| Medvedovici, A | 2 |
| Monciu, CM | 1 |
| Han, F | 1 |
| Zhao, H | 1 |
| Lin, ZJ | 1 |
| Huang, QM | 1 |
| Weng, N | 1 |
| Martín, J | 1 |
| Buchberger, W | 1 |
| Santos, JL | 1 |
| Alonso, E | 1 |
| Aparicio, I | 1 |
| Alsudir, S | 1 |
| Iqbal, Z | 1 |
| Lai, EP | 2 |
| Li, N | 1 |
| Deng, Y | 1 |
| Qin, F | 1 |
| Yu, J | 1 |
| Li, F | 1 |
| Sharma, K | 1 |
| Pawar, G | 1 |
| Yadam, S | 1 |
| Giri, S | 1 |
| Rajagopal, S | 1 |
| Mullangi, R | 1 |
| Roumie, CL | 1 |
| Hung, AM | 1 |
| Greevy, RA | 1 |
| Grijalva, CG | 1 |
| Liu, X | 1 |
| Murff, HJ | 1 |
| Elasy, TA | 1 |
| Griffin, MR | 1 |
| AbuRuz, S | 3 |
| Millership, J | 3 |
| McElnay, J | 3 |
| Kolte, BL | 2 |
| Raut, BB | 2 |
| Deo, AA | 2 |
| Bagool, MA | 2 |
| Shinde, DB | 2 |
| Chou, CH | 2 |
| Cheng, CL | 2 |
| Huang, CC | 1 |
| Tang, Y | 1 |
| Gu, J | 1 |
| Fawcett, JP | 1 |
| Bai, X | 1 |
| Herman, WH | 1 |
| Hoerger, TJ | 1 |
| Brandle, M | 1 |
| Hicks, K | 1 |
| Sorensen, S | 1 |
| Zhang, P | 1 |
| Hamman, RF | 1 |
| Ackermann, RT | 1 |
| Engelgau, MM | 1 |
| Ratner, RE | 1 |
| Wang, LR | 1 |
| Huang, MZ | 1 |
| Zhu, SH | 1 |
| Eddy, DM | 1 |
| Schlessinger, L | 1 |
| Kahn, R | 1 |
| Zhong, GP | 1 |
| Bi, HC | 1 |
| Zhou, S | 1 |
| Chen, X | 1 |
| Huang, M | 1 |
| Jiang, J | 1 |
| Feng, F | 1 |
| Ma, M | 1 |
| Zhang, ZX | 1 |
| Bergheim, I | 1 |
| Guo, L | 1 |
| Davis, MA | 1 |
| Lambert, JC | 1 |
| Beier, JI | 1 |
| Duveau, I | 1 |
| Luyendyk, JP | 1 |
| Roth, RA | 1 |
| Arteel, GE | 1 |
| Hoek, JB | 1 |
| Feng, SY | 1 |
| Ding, CG | 1 |
| Ge, QH | 1 |
| Zhi, XJ | 1 |
| Ma, LL | 1 |
| Marques, MA | 1 |
| Soares, Ade S | 1 |
| Pinto, OW | 1 |
| Barroso, PT | 1 |
| Pinto, DP | 1 |
| Ferreira-Filho, M | 1 |
| Werneck-Barroso, E | 1 |
| Zhang, L | 1 |
| Tian, Y | 1 |
| Zhang, Z | 1 |
| Chen, Y | 1 |
| Mistri, HN | 1 |
| Jangid, AG | 1 |
| Shrivastav, PS | 1 |
| Skrzypek, S | 1 |
| Mirceski, V | 1 |
| Ciesielski, W | 1 |
| Sokołowski, A | 1 |
| Zakrzewski, R | 1 |
| Ali, I | 1 |
| Aboul-Enein, HY | 1 |
| Gupta, VK | 1 |
| Zhao, XH | 1 |
| Song, B | 1 |
| Zhong, DF | 1 |
| Zhang, SQ | 1 |
| Chen, XY | 1 |
| Song, JZ | 1 |
| Chen, HF | 1 |
| Tian, SJ | 1 |
| Sun, ZP | 1 |
| Vesterqvist, O | 1 |
| Nabbie, F | 1 |
| Swanson, B | 1 |
| Bonfigli, AR | 1 |
| Manfrini, S | 1 |
| Gregorio, F | 1 |
| Testa, R | 1 |
| Testa, I | 1 |
| De Sio, G | 1 |
| Coppa, G | 1 |
| Zhang, M | 1 |
| Moore, GA | 1 |
| Lever, M | 1 |
| Gardiner, SJ | 1 |
| Kirkpatrick, CM | 1 |
| Begg, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-labelled Study to Characterise Fluciclovine (18F) Uptake Measured by positRon emissiON Tomography In Breast cancER[NCT03036943] | 40 participants (Actual) | Interventional | 2017-02-15 | Completed | |||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Comparative Effectiveness of Point-of-care Glycosylated Hemoglobin Measurement (POC-A1c) vs the Current Standard Based on Oral Glucose Tolerance Test for Early Detection of Type 2 Diabetes Mellitus (DM2) in Colombia[NCT05440968] | 902 participants (Actual) | Interventional | 2022-06-30 | Active, not recruiting | |||
| A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications[NCT00765817] | Phase 3 | 261 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Virtual Translation of Diabetes Prevention to Primary Care: A Pilot Study[NCT00729079] | 36 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| Helping the Poor Quit Smoking: Specialized Quitlines and Meeting Basic Needs[NCT03194958] | 1,944 participants (Actual) | Interventional | 2017-06-05 | Completed | |||
| Effect of the CAIPaDi Care Model in Relatives of Patients With Type 2 Diabetes Mellitus[NCT03234946] | 97 participants (Anticipated) | Interventional | 2017-06-19 | Active, not recruiting | |||
| A Combined Single Dose Study Under Fasting Condition And Multiple Doses Study Under Normal Diabetic Meal Comparing the Bioavailability of Two Formulations of 500 mg Metformin Hydrochloride Extended Release Tablets.[NCT01677260] | 38 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
Change in body weight following 30 weeks of therapy (i.e., body weight at week 30 minus body weight at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | kg (Least Squares Mean) |
|---|---|
| Exenatide Arm | -1.78 |
| Placebo Arm | 0.96 |
Change in daily insulin dose following 30 weeks of therapy (i.e., daily insulin dose at week 30 minus daily insulin dose at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | insulin units (U) (Least Squares Mean) |
|---|---|
| Exenatide Arm | 13.19 |
| Placebo Arm | 19.71 |
Change in daily insulin dose per kilogram (kg) following 30 weeks of therapy (i.e., daily insulin dose per kg at week 30 minus daily insulin dose per kg at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | insulin units per kg (U/kg) (Least Squares Mean) |
|---|---|
| Exenatide Arm | 0.15 |
| Placebo Arm | 0.20 |
Change in DBP following 30 weeks of therapy (i.e., DBP at week 30 minus DBP at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Exenatide Arm | -1.73 |
| Placebo Arm | 1.69 |
Change in fasting serum glucose following 30 weeks of therapy (i.e., fasting serum glucose at week 30 minus fasting serum glucose at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Exenatide Arm | -1.28 |
| Placebo Arm | -0.87 |
Change in HbA1c from baseline following 30 weeks of therapy (i.e., HbA1c at week 30 minus HbA1c at baseline). Unit of measure is percent of hemoglobin that is glycosylated. (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | percentage of hemoglobin (Least Squares Mean) |
|---|---|
| Exenatide Arm | -1.71 |
| Placebo Arm | -1.00 |
Change in HDL cholesterol following 30 weeks of therapy (i.e., HDL cholesterol at week 30 minus HDL cholesterol at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Exenatide Arm | 0.01 |
| Placebo Arm | 0.00 |
Change in LDL cholesterol following 30 weeks of therapy (i.e., LDL cholesterol at week 30 minus LDL cholesterol at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Exenatide Arm | -0.19 |
| Placebo Arm | -0.00 |
Change in SBP following 30 weeks of therapy (i.e., SBP at week 30 minus SBP at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Exenatide Arm | -2.74 |
| Placebo Arm | 1.71 |
Change in total cholesterol following 30 weeks of therapy (i.e., total cholesterol at week 30 minus total cholesterol at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Exenatide Arm | -0.16 |
| Placebo Arm | -0.02 |
Change in triglycerides following 30 weeks of therapy (i.e., triglycerides at week 30 minus triglycerides at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Exenatide Arm | -0.02 |
| Placebo Arm | -0.03 |
Change in waist circumference following 30 weeks of therapy (i.e., waist circumference at week 30 minus waist circumference at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | cm (Least Squares Mean) |
|---|---|
| Exenatide Arm | -1.08 |
| Placebo Arm | -0.25 |
Number of minor hypoglycemia events experienced per subject per year. Minor hypoglycemia was defined as any time a subject felt he or she was experiencing a sign or symptom associated with hypoglycemia that was either self-treated by the subject or resolved on its own and had a concurrent finger stick blood glucose <3.0 mmol/L (54 mg/dL). (NCT00765817)
Timeframe: baseline and weeks 2, 4, 6, 8, 10, 14, 18, 22, 26, and 30
| Intervention | events per subject per year (Mean) |
|---|---|
| Exenatide Arm | 1.61 |
| Placebo Arm | 1.55 |
Percentage of patients in each arm who had HbA1c >6.5% at baseline and had HbA1c <=6.5% at week 30 (percentage = [number of subjects with HbA1c <=6.5% at week 30 divided by number of subjects with HbA1c >6.5% at baseline] * 100%). (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | percentage (Number) |
|---|---|
| Exenatide Arm | 42.0 |
| Placebo Arm | 13.3 |
Percentage of patients in each arm who had HbA1c >7% at baseline and had HbA1c <=7% at week 30 (percentage = [number of subjects with HbA1c <=7% at week 30 divided by number of subjects with HbA1c >7% at baseline] * 100%). (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | percentage (Number) |
|---|---|
| Exenatide Arm | 58.3 |
| Placebo Arm | 31.1 |
Percentage of subjects in each arm experiencing at least one episode of minor hypoglycemia at any point during the study. Minor hypoglycemia was defined as any time a subject felt he or she was experiencing a sign or symptom associated with hypoglycemia that was either self-treated by the subject or resolved on its own and had a concurrent finger stick blood glucose <3.0 mmol/L (54 mg/dL). (NCT00765817)
Timeframe: baseline and weeks 2, 4, 6, 8, 10, 14, 18, 22, 26, and 30
| Intervention | percentage (Number) |
|---|---|
| Exenatide Arm | 24.8 |
| Placebo Arm | 28.7 |
Change in 7-point (pre-breakfast, 2 hour post-breakfast, pre-lunch, 2 hour post-lunch, pre-dinner, 2 hour post-dinner, 0300 hours) SMBG profile from baseline to week 30 (change = blood glucose value at week 30 minus blood glucose value at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-breakfast: baseline | Pre-breakfast: change at week 30 | 2 hour post-breakfast: baseline | 2 hour post-breakfast: change at week 30 | Pre-lunch: baseline | Pre-lunch: change at week 30 | 2 hour post-lunch: baseline | 2 hour post-lunch: change at week 30 | Pre-dinner: baseline | Pre-dinner: change at week 30 | 2 hour post-dinner: baseline | 2 hour post-dinner: change at week 30 | 0300: baseline | 0300: change at week 30 | |
| Exenatide Arm | 7.89 | -1.58 | 10.89 | -3.56 | 8.95 | -2.23 | 11.35 | -2.74 | 9.85 | -2.25 | 12.03 | -3.87 | 8.95 | -2.27 |
| Placebo Arm | 8.27 | -1.48 | 11.82 | -1.72 | 9.77 | -1.15 | 11.70 | -1.38 | 9.99 | -1.33 | 11.86 | -1.34 | 9.20 | -1.48 |
Report quitting smoking for at least 24 hours during intervention (NCT03194958)
Timeframe: 6 months post-baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Quitline | 241 |
| Specialized Quitline | 219 |
| Standard Quitline With Basic Needs Navigator | 248 |
| Specialized Quitline With Basic Needs Navigator | 235 |
Report 7-day point prevalence abstinence measured at 3-months post-baseline (NCT03194958)
Timeframe: 3 months post-baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Quitline | 97 |
| Specialized Quitline | 104 |
| Standard Quitline With Basic Needs Navigator | 80 |
| Specialized Quitline With Basic Needs Navigator | 105 |
Report 7-day point prevalence abstinence measured at 6-months post --baseline (NCT03194958)
Timeframe: 6 months post-baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Quitline | 101 |
| Specialized Quitline | 90 |
| Standard Quitline With Basic Needs Navigator | 74 |
| Specialized Quitline With Basic Needs Navigator | 103 |
5 reviews available for metformin and Sensitivity and Specificity
| Article | Year |
|---|---|
Taming expectations of metformin as a treatment to extend healthspan.
Topics: Aged; Aged, 80 and over; Aging; Female; Geriatrics; Humans; Hypoglycemic Agents; Longevity; Male; Me | 2019 |
Relationship of the Serum CRP Level With the Efficacy of Metformin in the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis.
Topics: Adult; Aged; C-Reactive Protein; Databases as Topic; Diabetes Mellitus, Type 2; Female; Humans; Male | 2016 |
Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Glycated Hemoglobin; H | 2017 |
Treating prediabetes with metformin: systematic review and meta-analysis.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dr | 2009 |
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptid | 2009 |
7 trials available for metformin and Sensitivity and Specificity
| Article | Year |
|---|---|
Characterising
Topics: Breast Neoplasms; Carboxylic Acids; Cyclobutanes; Female; Humans; Metformin; Neoplasm Grading; Posit | 2022 |
Agreement of 2D transthoracic echocardiography with cardiovascular magnetic resonance imaging after ST-elevation myocardial infarction.
Topics: Cardiovascular Agents; Drug Administration Schedule; Echocardiography; Female; Heart Ventricles; Hum | 2019 |
Correlates of Medication Adherence in the TODAY Cohort of Youth With Type 2 Diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Cohort Studies; Depression; Diabetes Mellitus, Ty | 2016 |
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Dru | 2011 |
Linearization of the MS response function: case study for metformin assay in plasma samples for bioequivalence purposes.
Topics: Chromatography, Liquid; Cross-Over Studies; Humans; Linear Models; Metformin; Models, Statistical; R | 2012 |
Simultaneous assay of metformin and glibenclamide in human plasma based on extraction-less sample preparation procedure and LC/(APCI)MS.
Topics: Adult; Chromatography, Liquid; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Mass Spectromet | 2007 |
Determination of plasma metformin by a new cation-exchange HPLC technique.
Topics: Administration, Oral; Aged; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Diab | 1999 |
68 other studies available for metformin and Sensitivity and Specificity
| Article | Year |
|---|---|
Metformin-sensitized NSCLC cells to osimertinib via AMPK-dependent autophagy inhibition.
Topics: Acrylamides; AMP-Activated Protein Kinases; Aniline Compounds; Autophagy; Carcinoma, Non-Small-Cell | 2019 |
Metformin limits osteoarthritis development and progression through activation of AMPK signalling.
Topics: AMP-Activated Protein Kinases; Animals; Cartilage, Articular; Cells, Cultured; Chondrocytes; Disease | 2020 |
Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions.
Topics: Administration, Oral; Adult; Canagliflozin; Chromatography, High Pressure Liquid; Drug Combinations; | 2020 |
Identifying patients with metformin associated lactic acidosis in the emergency department.
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Creatinine; Emergency Service, Hospital; Female; Humans; | 2020 |
Developing an analytical method by HPLC for simultaneous quantification of methylene blue and metformin applied to in vitro skin permeation and retention studies.
Topics: Animals; Chromatography, High Pressure Liquid; Linear Models; Metformin; Methylene Blue; Reproducibi | 2021 |
Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Brain Neoplasms; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; M | 2021 |
Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications.
Topics: Adolescent; Adult; Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studi | 2017 |
Comparative study between UHPLC-UV and UPLC-MS/MS methods for determination of alogliptin and metformin in their pharmaceutical combination.
Topics: Chromatography, High Pressure Liquid; Drug Combinations; Hypoglycemic Agents; Metformin; Piperidines | 2017 |
Quantitative determination of metformin, saxagliptin and 5-hydroxy saxagliptin simultaneously by hydrophilic interaction liquid chromatography - electrospray ionization mass spectrometry and its application to a bioequivalence study with a single-pill com
Topics: Adamantane; Chromatography, Liquid; Dipeptides; Drug Combinations; Humans; Hydrophobic and Hydrophil | 2018 |
An HPLC method for the determination of adenosine diphosphate: An important marker of hexokinase activity in metabolic diseases.
Topics: Adenosine Diphosphate; Animals; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, | 2019 |
Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide.
Topics: Chromatography, High Pressure Liquid; Gliclazide; Hypoglycemic Agents; Limit of Detection; Metformin | 2019 |
Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance.
Topics: Animals; Biological Products; Biopsy, Needle; Carbamates; Disease Models, Animal; Glucose Intoleranc | 2019 |
A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers.
Topics: Benzhydryl Compounds; Canagliflozin; Chromatography, High Pressure Liquid; Glucosides; Humans; Linea | 2019 |
Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study.
Topics: Chromatography, Liquid; Drug Stability; Humans; Male; Metformin; Pioglitazone; Reproducibility of Re | 2013 |
Development of validated stability indicating assay method for simultaneous estimation of metformin hydrochloride and vildagliptin by RP-HPLC.
Topics: Adamantane; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse | 2014 |
Quantitation of metformin in human plasma and urine by hydrophilic interaction liquid chromatography and application to a pharmacokinetic study.
Topics: Chromatography, Liquid; Healthy Volunteers; Humans; Hydrophobic and Hydrophilic Interactions; Hypogl | 2014 |
Quantitative determination of metformin, glyburide and its metabolites in plasma and urine of pregnant patients by LC-MS/MS.
Topics: Adult; Chromatography, High Pressure Liquid; Diabetes, Gestational; Female; Glyburide; Humans; Hypog | 2015 |
Development and validation of fast and simple flow injection analysis-tandem mass spectrometry (FIA-MS/MS) for the determination of metformin in dog serum.
Topics: Animals; Dogs; Flow Injection Analysis; Metformin; Reproducibility of Results; Sensitivity and Speci | 2015 |
Application of HPLC mixed-mode chromatography in determining radiochemical purity of [(14) C] labeled metformin hydrochloride.
Topics: Carbon Radioisotopes; Chromatography, High Pressure Liquid; Isotope Labeling; Materials Testing; Met | 2015 |
Development and Validation of a Method for Simultaneous Estimation of Metformin and Sitagliptin in Human Plasma by LC-MS-MS and Its Application in a Bioequivalence Study.
Topics: Chromatography, Liquid; Drug Stability; Humans; Metformin; Reproducibility of Results; Sensitivity a | 2015 |
Analysis of metformin, sitagliptin and creatinine in human dried blood spots.
Topics: Creatinine; Diabetes Mellitus; Dried Blood Spot Testing; Drug Stability; Humans; Hypoglycemic Agents | 2015 |
Personalized Diabetes Management Using Electronic Medical Records.
Topics: Aged; Blood Glucose; Body Mass Index; Boston; Diabetes Mellitus, Type 2; Disease Management; Drug Th | 2017 |
Homeostasis model assessment-insulin resistance (HOMA-IR), a key role for assessing the ovulation function in polycystic ovary syndrome (PCOS) patients with insulin resistance.
Topics: Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Homeostasis; Humans; Hypoglycemic | 2008 |
Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and glimepiride by RP-HPLC in tablet formulation.
Topics: Chromatography, High Pressure Liquid; Hypoglycemic Agents; Metformin; Pioglitazone; Reference Standa | 2008 |
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Cross-Sectional Studies; Cytokines; Diabetes Mellitus, Type 2 | 2010 |
If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Clinical Trials as Topic; Drug Deli | 2009 |
Metformin use in patients with diabetes mellitus and heart failure: friend or foe?
Topics: Diabetes Mellitus, Type 2; Female; Heart Failure, Systolic; Humans; Hypoglycemic Agents; Male; Metfo | 2010 |
LC-MS/MS method using unbonded silica column and aqueous/methanol mobile phase for the simultaneous quantification of a drug candidate and co-administered metformin in rat plasma.
Topics: Acetonitriles; Animals; Bicarbonates; Calibration; Chromatography, Liquid; Drug Discovery; Formates; | 2010 |
Simultaneous determination of metformin, cimetidine, famotidine, and ranitidine in human serum and dosage formulations using HPLC with UV detection.
Topics: Adult; Chromatography, High Pressure Liquid; Cimetidine; Ethylamines; Famotidine; Histamine H2 Antag | 2010 |
Ultra-performance hydrophilic interaction LC-MS/MS for the determination of metformin in mouse plasma.
Topics: Animals; Chromatography, Liquid; Chromatography, Reverse-Phase; Metformin; Mice; Sensitivity and Spe | 2009 |
Metformin and the incidence of prostate cancer in patients with type 2 diabetes.
Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hy | 2011 |
Simultaneous determination and pharmacokinetic study of metformin and rosiglitazone in human plasma by HPLC-ESI-MS.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Least-Squares Analysis; Male; | 2011 |
Simultaneous quantitation of metformin and sitagliptin from mouse and human dried blood spots using laser diode thermal desorption tandem mass spectrometry.
Topics: Animals; Blood Stains; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Drug Stora | 2011 |
Determination of metformin in rat plasma by HILIC-MS/MS combined with Tecan automation and direct injection.
Topics: Animals; Chromatography, Liquid; Drug Stability; High-Throughput Screening Assays; Hydrophobic and H | 2012 |
High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples.
Topics: Chromatography, High Pressure Liquid; Drinking Water; Glyburide; Hydrogen-Ion Concentration; Hypogly | 2012 |
Competitive CE-UV binding tests for selective recognition of bisphenol A by molecularly imprinted polymer particles.
Topics: Benzhydryl Compounds; Binding, Competitive; Diclofenac; Electrophoresis, Capillary; Hydrogen-Ion Con | 2012 |
Simultaneous quantification of metformin and glipizide in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Topics: Adult; Chromatography, High Pressure Liquid; Drug Stability; Glipizide; Humans; Linear Models; Male; | 2013 |
LC-MS/MS-ESI method for simultaneous quantitation of metformin and repaglinidie in rat plasma and its application to pharmacokinetic study in rats.
Topics: Animals; Carbamates; Chromatography, Liquid; Drug Stability; Linear Models; Male; Metformin; Piperid | 2013 |
Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Topics: Aged; Cause of Death; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglycemic Agent | 2012 |
Determination of metformin in plasma using a new ion pair solid phase extraction technique and ion pair liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Humans; Metformin; Reproducibility of Results; Sensitivity and | 2003 |
Simultaneous high-performance liquid chromatographic determination of pioglitazone and metformin in pharmaceutical-dosage form.
Topics: Chromatography, High Pressure Liquid; Dosage Forms; Hypoglycemic Agents; Metformin; Pharmaceutical P | 2004 |
Simultaneous determination of metformin in combination with rosiglitazone by reversed-phase liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Metformin; Reference Standards; Reproducibility of Results; Ro | 2004 |
A validated HPLC method with ultraviolet detection for the determination of buformin in plasma.
Topics: Animals; Antipsychotic Agents; Buformin; Calibration; Chromatography, High Pressure Liquid; Hypoglyc | 2004 |
Rapid and sensitive liquid chromatography-tandem mass spectrometric method for the quantitation of metformin in human plasma.
Topics: Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Mass Spectrometry; Metformin; Rep | 2004 |
The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma.
Topics: Chromatography, High Pressure Liquid; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; | 2005 |
Summaries for patients. The cost-effectiveness of strategies to prevent type 2 diabetes.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
[HPLC determination of metformin hydrochloride-related substances].
Topics: Chromatography, High Pressure Liquid; Guanidines; Hypoglycemic Agents; Metformin; Sensitivity and Sp | 2005 |
Summaries for patients. The outcomes and costs of diabetes prevention with a diet and exercise program or metformin: a computer model.
Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2 | 2005 |
Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2 | 2005 |
Simultaneous determination of metformin and gliclazide in human plasma by liquid chromatography-tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy volunteers.
Topics: Calibration; Chromatography, Liquid; Gliclazide; Health; Humans; Metformin; Molecular Structure; Sen | 2005 |
Dried blood spot liquid chromatography assay for therapeutic drug monitoring of metformin.
Topics: Drug Monitoring; Humans; Hypoglycemic Agents; Metformin; Reference Standards; Sensitivity and Specif | 2006 |
Study on a new precolumn derivatization method in the determination of metformin hydrochloride.
Topics: Calibration; Humans; Hypoglycemic Agents; Metformin; Reproducibility of Results; Sensitivity and Spe | 2006 |
Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1.
Topics: Animals; Animals, Newborn; Biopsy, Needle; Cells, Cultured; Disease Models, Animal; Ethanol; Immunoh | 2006 |
Metformin and the fate of fat.
Topics: Animals; Disease Models, Animal; Fats; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabo | 2006 |
Solid phase extraction--non-aqueous capillary electrophoresis for determination of metformin, phenformin and glyburide in human plasma.
Topics: Electrophoresis, Capillary; Glyburide; Humans; Hypoglycemic Agents; Metformin; Phenformin; Reference | 2006 |
Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Glipizide; Humans; Male; Metformin; Reproducib | 2007 |
Simple and rapid method determination for metformin in human plasma using high performance liquid chromatography tandem mass spectrometry: application to pharmacokinetic studies.
Topics: Calibration; Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Metformin; Reference | 2007 |
Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study.
Topics: Chromatography, Liquid; Humans; Hypoglycemic Agents; Metformin; Reproducibility of Results; Rosiglit | 2007 |
Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glyburide in human plasma.
Topics: Chromatography, High Pressure Liquid; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Repro | 2007 |
Direct determination of metformin in urine by adsorptive catalytic square-wave voltammetry.
Topics: Acetates; Adsorption; Buffers; Catalysis; Chromatography, High Pressure Liquid; Electrochemistry; El | 2007 |
Analysis of metformin dosage formulations by capillary electrophoresis at nano scale detection.
Topics: Electrophoresis, Capillary; Linear Models; Metformin; Nanotechnology; Pharmaceutical Preparations; R | 2007 |
[Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry].
Topics: Administration, Oral; Chromatography, Liquid; Glipizide; Humans; Hypoglycemic Agents; Male; Metformi | 2007 |
Determination of metformin in plasma by capillary electrophoresis using field-amplified sample stacking technique.
Topics: Drug Stability; Electrophoresis, Capillary; Humans; Metformin; Reproducibility of Results; Sensitivi | 1998 |
Simple high-performance liquid chromatographic method for the determination of metformin in human plasma.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Evaluation Studies as Topic; H | 1998 |
Determination of metformin in plasma by high-performance liquid chromatography after ultrafiltration.
Topics: Anticoagulants; Blood Proteins; Chromatography, High Pressure Liquid; Edetic Acid; Freezing; Heparin | 1998 |
Determination of metformin in human plasma by high-performance liquid chromatography with spectrophotometric detection.
Topics: Animals; Calibration; Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Metformin; | 2001 |
Rapid and simple high-performance liquid chromatographic assay for the determination of metformin in human plasma and breast milk.
Topics: Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Metformin; Milk, Human; Reference | 2002 |